Amedisys (NASDAQ:AMED) Receives New Coverage from Analysts at Deutsche Bank

Deutsche Bank began coverage on shares of Amedisys (NASDAQ:AMED) in a research note released on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $155.00 target price on the health services provider’s stock.

Several other research firms have also recently weighed in on AMED. BidaskClub raised Amedisys from a buy rating to a strong-buy rating in a report on Friday, July 26th. ValuEngine raised Amedisys from a hold rating to a buy rating in a report on Thursday, September 5th. Jefferies Financial Group set a $150.00 price target on Amedisys and gave the company a buy rating in a report on Monday, July 8th. Barclays raised their price target on Amedisys from $120.00 to $125.00 and gave the company an equal weight rating in a report on Monday, August 5th. Finally, Raymond James raised their price target on Amedisys from $140.00 to $144.00 and gave the company an outperform rating in a report on Monday, July 15th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $138.59.

NASDAQ:AMED opened at $132.09 on Monday. The business’s 50-day moving average price is $132.48 and its two-hundred day moving average price is $123.75. Amedisys has a twelve month low of $97.38 and a twelve month high of $141.98. The stock has a market cap of $4.30 billion, a P/E ratio of 36.39, a PEG ratio of 1.96 and a beta of 1.46. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 0.58.

Amedisys (NASDAQ:AMED) last released its quarterly earnings results on Wednesday, July 31st. The health services provider reported $1.21 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.24. Amedisys had a return on equity of 27.23% and a net margin of 6.84%. The firm had revenue of $492.98 million for the quarter, compared to analysts’ expectations of $489.66 million. During the same quarter last year, the firm posted $1.00 EPS. The company’s revenue was up 19.8% compared to the same quarter last year. On average, equities research analysts expect that Amedisys will post 4.13 EPS for the current fiscal year.

In related news, insider Michael Paul North sold 10,067 shares of the firm’s stock in a transaction dated Wednesday, July 24th. The stock was sold at an average price of $130.00, for a total transaction of $1,308,710.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Scott G. Ginn sold 4,871 shares of the firm’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $132.06, for a total value of $643,264.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,749 shares of company stock worth $2,986,811. 2.90% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Timpani Capital Management LLC grew its position in Amedisys by 117.3% during the 1st quarter. Timpani Capital Management LLC now owns 20,817 shares of the health services provider’s stock worth $2,566,000 after acquiring an additional 11,237 shares during the last quarter. BBT Capital Management LLC bought a new position in Amedisys during the 1st quarter worth approximately $295,000. Dynamic Technology Lab Private Ltd grew its position in Amedisys by 85.0% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 3,266 shares of the health services provider’s stock worth $403,000 after acquiring an additional 1,501 shares during the last quarter. Citigroup Inc. grew its position in Amedisys by 125.7% during the 1st quarter. Citigroup Inc. now owns 28,527 shares of the health services provider’s stock worth $3,516,000 after acquiring an additional 15,890 shares during the last quarter. Finally, Capital Fund Management S.A. grew its position in Amedisys by 8.6% during the 2nd quarter. Capital Fund Management S.A. now owns 66,398 shares of the health services provider’s stock worth $8,061,000 after acquiring an additional 5,261 shares during the last quarter. Institutional investors and hedge funds own 88.53% of the company’s stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Read More: CBOE Russell 2000® Volatility Index

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit